Visceral and Dysfunctional Adiposity Indices as Predictors of Insulin Resistance and Metabolic Syndrome in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study.
| Title: | Visceral and Dysfunctional Adiposity Indices as Predictors of Insulin Resistance and Metabolic Syndrome in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study. |
|---|---|
| Authors: | Keyif B; Department of Obstetrics and Gynecology, Faculty of Medicine, Düzce University, 81620 Düzce, Turkey.; Yavuzcan A; Department of Obstetrics and Gynecology, Faculty of Medicine, Sağlık Bilimleri University, Ankara Bilkent City Hospital, 06800 Ankara, Turkey. |
| Source: | Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2025 Feb 28; Vol. 61 (3). Date of Electronic Publication: 2025 Feb 28. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 9425208 Publication Model: Electronic Cited Medium: Internet ISSN: 1648-9144 (Electronic) Linking ISSN: 1010660X NLM ISO Abbreviation: Medicina (Kaunas) Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2018- : Basel, Switzerland : MDPI; Original Publication: Kaunas : Lietuvos gydytojų sąjunga |
| MeSH Terms: | Polycystic Ovary Syndrome*/complications ; Polycystic Ovary Syndrome*/physiopathology ; Metabolic Syndrome*/physiopathology ; Metabolic Syndrome*/diagnosis ; Metabolic Syndrome*/etiology ; Insulin Resistance*/physiology ; Intra-Abdominal Fat*/physiopathology ; Adiposity*/physiology; Biomarkers/analysis ; Biomarkers/blood ; Humans ; Female ; Cross-Sectional Studies ; Adult ; ROC Curve |
| Abstract: | Background and Objectives: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age. Women with PCOS often have metabolic disorders such as insulin resistance (IR), type 2 diabetes (T2DM), obesity, and metabolic syndrome (MetS). The assessment of visceral adiposity and dysfunctional adipose tissue is crucial for understanding the metabolic risks associated with PCOS. The visceral adiposity index (VAI) and the dysfunctional adiposity index (DAI) are two novel metabolic indices that more specifically assess adipose tissue dysfunction and visceral fat accumulation. This study aimed to evaluate the clinical utility of VAI and DAI as predictive markers for metabolic complications such as insulin resistance (IR) and metabolic syndrome (MetS) in women with PCOS. Materials and Methods: This cross-sectional study included 92 women diagnosed with PCOS based on the 2023 revised Rotterdam criteria, as well as 68 healthy controls. Anthropometric and biochemical parameters, including fasting glucose, insulin, lipid profile, and hormonal markers, were recorded. VAI and DAI were calculated using established formulas derived from previous validated studies. Results: The mean VAI in PCOS patients was 4.26 ± 3.23, compared to 2.61 ± 1.92 in controls (p = 0.003). The mean DAI in PCOS patients was 3.00 ± 1.86, while in controls it was 1.86 ± 1.22 (p = 0.003). Both VAI (Area Under the Curve [AUC] = 0.639) and DAI (AUC = 0.635) did not demonstrate statistically significant diagnostic performance for PCOS itself, but they were strongly associated with metabolic disturbances within the PCOS group. VAI and DAI values were significantly elevated in PCOS patients with IR (p < 0.001) and MetS (p < 0.001). For MetS in PCOS patients, VAI demonstrated the highest predictive ability, with an AUC of 0.87 and a cutoff of 4.73 (sensitivity 62%, specificity 92%), while DAI had an AUC of 0.86 with a cutoff of 2.44 (sensitivity 74%, specificity 80%). Regarding IR in PCOS patients, VAI had an AUC of 0.75 with a cutoff of 2.56 (sensitivity 82%, specificity 56%), while DAI had an AUC of 0.74 with a cutoff of 1.59, showing a sensitivity of 82% and a specificity of 55%. Conclusions: Although VAI and DAI are not suitable for diagnosing PCOS, they provide valuable insights into the metabolic risks associated with the condition. VAI and DAI can serve as promising biomarkers for identifying IR and MetS risk in women with PCOS. Their integration into clinical practice may facilitate the early detection of cardiometabolic complications, offering a more specific metabolic risk assessment compared to traditional anthropometric measures. |
| References: | Int J Endocrinol Metab. 2017 Jul 30;15(4):e12353. (PMID: 29344030); Obesity (Silver Spring). 2013 Aug;21(8):1690-4. (PMID: 23585246); Adipocyte. 2021 Dec;10(1):142-152. (PMID: 33722154); Noro Psikiyatr Ars. 2014 Jun;51(2):129-132. (PMID: 28360612); Clin Res Hepatol Gastroenterol. 2020 Jun;44(3):375-383. (PMID: 32434704); J Pediatr. 2023 Feb;253:33-39.e3. (PMID: 36115621); Reprod Sci. 2023 Jan;30(1):28-40. (PMID: 35107824); Gynecol Endocrinol. 2024 Dec;40(1):2405097. (PMID: 39305479); Sci Rep. 2022 Sep 15;12(1):15486. (PMID: 36109524); BMC Med. 2011 May 05;9:48. (PMID: 21542944); Int J Mol Sci. 2022 Jan 06;23(2):. (PMID: 35054768); Sci Rep. 2025 Feb 12;15(1):5284. (PMID: 39939752); Int J Environ Res Public Health. 2022 May 01;19(9):. (PMID: 35564900); BMC Med. 2023 Feb 20;21(1):62. (PMID: 36800955); J Clin Med. 2023 Feb 14;12(4):. (PMID: 36836035); J Clin Endocrinol Metab. 2023 Dec 21;109(1):10-24. (PMID: 37329216); Cureus. 2024 May 24;16(5):e60975. (PMID: 38800769); Int J Cardiol. 2016 Dec 15;225:387-391. (PMID: 27768965); Eur Rev Med Pharmacol Sci. 2022 Oct;26(19):7182-7187. (PMID: 36263527); J Diabetes Investig. 2022 Mar;13(3):543-551. (PMID: 34592063); Nutrients. 2025 Jan 23;17(3):. (PMID: 39940263); BMC Public Health. 2024 Jan 9;24(1):121. (PMID: 38191327); J Endocrinol Invest. 2017 May;40(5):487-497. (PMID: 27838846); Antioxidants (Basel). 2021 Mar 13;10(3):. (PMID: 33805781); Endocr Pract. 2025 Feb 11;:. (PMID: 39947624); BMC Med Imaging. 2023 Sep 14;23(1):127. (PMID: 37710156); Arch Gynecol Obstet. 2025 Feb 13;:. (PMID: 39945793); Cureus. 2022 May 17;14(5):e25076. (PMID: 35719759); Nutr Metab Cardiovasc Dis. 2024 Aug;34(8):2002-2011. (PMID: 38664129); BMC Endocr Disord. 2024 Aug 28;24(1):160. (PMID: 39198818); BMC Public Health. 2022 Oct 17;22(1):1928. (PMID: 36253740); Semergen. 2023 Sep;49(6):101965. (PMID: 37075595); Diabetes Metab Syndr Obes. 2023 Feb 17;16:495-504. (PMID: 36824322); Medicina (Kaunas). 2019 May 17;55(5):. (PMID: 31108989); Gynecol Endocrinol. 2013 Feb;29(2):141-4. (PMID: 23116196); Diagnostics (Basel). 2023 Mar 15;13(6):. (PMID: 36980421) |
| Contributed Indexing: | Keywords: adiposity indices; insulin resistance; metabolic risk assessment; metabolic syndrome |
| Substance Nomenclature: | 0 (Biomarkers) |
| Entry Date(s): | Date Created: 20250327 Date Completed: 20250514 Latest Revision: 20250514 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC11944119 |
| DOI: | 10.3390/medicina61030424 |
| PMID: | 40142235 |
| Database: | MEDLINE |
Journal Article